Alpine Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Alpine Study. Real-time updates on events, politics, business and more.

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

December 20, 2023

Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

San Diego United States Jenniferr Brown Extended Follow Up Zanubrutinib Versus Ibrutinib Refractory Chronic Lymphocytic Leukemia

Source: onclive.com

CLL: Supportive Care and Managing Adverse Effects With BTK Inhibitors

April 24, 2023

Insights on supportive care and approaches to managing adverse effects of BTK inhibitors in the treatment of chronic lymphocytic leukemia.

Hoshiyuki Iida Gloria Leslie Chronic Lymphocytic Leukemia Adverse Effects Atrial Fibrillation Supportive Care

Source: curetoday.com

Head-to-Head Studies on BTK Inhibitors in CLL

April 17, 2023

CLL expert Lori A. Leslie, MD, gives a comprehensive overview of the ALPINE and ELEVATE-RR head-to-head studies of BTK inhibitors in CLL.

Gloria Leslie Chronic Lymphocytic Leukemia Covalent Btk Inhibitors Elevate Rr Del 11q Del 17p

Source: curetoday.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Alpine Study News Today

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

CLL: Supportive Care and Managing Adverse Effects With BTK Inhibitors

Head-to-Head Studies on BTK Inhibitors in CLL

Explore More Categories